Zacks Reiterates Neutral on Gen-Probe Incorporated (GPRO)

By admin | 6 years ago

Gen-Probe Incorporated (NASDAQ: GPRO)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued to investors on Wednesday. They currently have a $85.00 price target on the stock.

A number of other analysts have also recently weighed in on GPRO. Analysts at Robert W. Baird downgraded shares of Gen-Probe Incorporated from an “outperform” rating to a “neutral” rating in a research note to investors on Friday, May 4th. They now have a $83.00 price target on the stock. Separately, analysts at RBC Capital (NYSE: RY) downgraded shares of Gen-Probe Incorporated from an “outperform” rating to a “sector perform” rating in a research note to investors on Tuesday, May 1st. They now have a $82.75 price target on the stock, up previously from $72.00. Finally, analysts at ThinkEquity downgraded shares of Gen-Probe Incorporated from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, May 1st.

Gen-Probe Incorporated opened at 81.20 on Wednesday. Gen-Probe Incorporated has a 1-year low of $53.92 and a 1-year high of $86.96. The company has a market cap of $3.677 billion and a price-to-earnings ratio of 78.68.

Gen-Probe Incorporated last released its earnings data on Monday, April 30th. The company reported $0.55 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.51 by $0.04. Gen-Probe Incorporated’s revenue was up 7.3% compared to the same quarter last year. Analysts expect that Gen-Probe Incorporated will post $0.67 EPS next quarter.

Gen-Probe Incorporated (Gen-Probe) is engaged in the development, manufacture and marketing molecular diagnostic products and services, which are used primarily to diagnose human diseases, screen donated human blood, and ensures transplant compatibility.

About the author